ClinicalTrials.gg
CompletedNCT07053930Updated Jul 8, 2025

Comparison of the Mean Duration of 3rd Stage of Labour Between Intraumbilical and Intravenous Oxytocin

An interventional study of Intraumbilical oxytocin and Intravenous oxytocin in Labor, sponsored by RESnTEC, Institute of Research. Completed at 1 site in Pakistan. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-07-08.

Sponsored by RESnTEC, Institute of Research · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Oct 2024, registered Jun 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

There is always a debate for choosing the best method for management of the third stage of labour (TSL) in the general practice for reducing the duration of TSL. Although intravenous oxytocin is more extensively used in general practice for managing TSL than intraumbilical, it still needs to be properly investigated among local populations and in local settings.

Read the detailed description

The findings of this study could identify the better route of oxytocin injection that could guide clinicians and health providers to opt for the better route in their routine practice for the management of TSL in order to reduce the morbidity and mortality of the patients, especially for developing countries like Pakistan, where most of the deliveries are conducted at peripheral or rural centers by a nurse, midwife, or a trained dai.

02

Conditions studied

  • Labor
03

In context

Lead sponsor

RESnTEC, Institute of Research is the lead sponsor of 16 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females aged 18-40 years
  • With spontaneous vaginal delivery
  • Singleton pregnancy
  • Gestational age >37 weeks
  • Parity l-5
  • Any gravidity

Exclusion criteria

Exclusion Criteria:

  • Females with intrauterine fetal death
  • Malpresentation
  • Multiple pregnancy
  • Polyhydramnios
  • Premature rupture of membranes
  • Medical disorders and hypertensive disorders of pregnancy
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Intraumbilical oxytocin group

    Patients were given 10 U of intraumbilical oxytocin, diluted in 10 mL of normal saline.

    Drug: Intraumbilical oxytocin

  • Experimental
    Intravenous oxytocin group

    Patients received 20 U of intravenous oxytocin diluted in 500 mL of normal saline.

    Drug: Intravenous oxytocin

Interventions

  • DrugIntraumbilical oxytocin

    Patients were given 10 U of intraumbilical oxytocin, diluted in 10 mL of normal saline.

  • DrugOxytocinStudies of OxytocinOxytocin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients received 20 U of intravenous oxytocin diluted in 500 mL of normal saline.

06

What researchers measure

Primary outcomes

  1. Duration of the third stage labour

    The duration of the third stage labour was measured from the completed delivery of the newborn until the completed delivery of the placenta.

    Time frame: 30 minutes

07

Study locations

1 site
  • Sadiq Abbasi Hospital
    Bahawalpur, Punjab Province 63100, Pakistan
08

References and documents

Individual participant data

Plan to share: No — Data can be shared on a reasonable request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in Mar 2025, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2025
First posted
Jul 8, 2025
StartActual
Oct 1, 2024
Primary completionActual
Mar 31, 2025
CompletionActual
Mar 31, 2025
Last update
Jul 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07053930
Lead sponsor
RESnTEC, Institute of Research
Responsible party
Sponsor
First posted
Jul 8, 2025
Start date
Oct 1, 2024
Primary completion
Mar 31, 2025
Completion
Mar 31, 2025
Last update
Jul 8, 2025

Study contacts

Anam Javed
principal investigator · Sadiq Abbasi Hospital, Bahawalpur, Pakistan
Komal Iqbal
principal investigator · Sadiq Abbasi Hospital, Bahawalpur, Pakistan

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxytocin

Start the discussion